[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.158.167.137. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Commentary
March 11, 2009

The CMS Ruling on Venous Thromboembolism After Total Knee or Hip ArthroplastyWeighing Risks and Benefits

Author Affiliations

Author Affiliations: Departments of Medicine (Dr Streiff), Pathology (Dr Streiff), and Surgery (Dr Haut), Johns Hopkins University School of Medicine, Baltimore, Maryland.

JAMA. 2009;301(10):1063-1065. doi:10.1001/jama.301.10.1063

In August 2008, the US Centers for Medicare & Medicaid Services (CMS) added deep venous thrombosis and pulmonary embolism after total knee arthroplasty (TKA) and total hip arthroplasty (THA) to the list of never events.1 If a patient experiences deep venous thrombosis or pulmonary embolism following one of these procedures, a portion of the payment made by CMS to hospitals is to be withheld. On the surface this decision seems to be a win-win for hospitals, clinicians, and patients. Venous thromboembolism (VTE) is a common cause of preventable harm,2 yet many hospitalized patients fail to receive adequate VTE prophylaxis.3 Accordingly, the strategy of using financial incentives to encourage better performance should result in fewer thrombotic events and consequently less morbidity and mortality related to VTE and its treatment.

First Page Preview View Large
First page PDF preview
First page PDF preview
×